Tracer library / [177Lu]Lu-DOTA-cyclo-MG1

[177Lu]Lu-DOTA-cyclo-MG1

Also written as [177Lu]Lu-DOTA-cyclo-MG1

Radionuclide: Lu-177
Modality: —
Production route: —
Stage: Preclinical
Syntheses indexed: 1

What it is

Compound class: Cyclic minigastrin analogue (DOTA-conjugated peptide)
Target / mechanism: Cholecystokinin-2 receptor (CCK2R/CCK-2) PMID 28728415
Clinical application: Targeted radionuclide therapy of CCK2R-expressing tumors, including medullary thyroid carcinoma PMID 21732165
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Kit-based preparation	—	—	>99	89.4±7.9	DOTA-cyclo-MG1 CSBio, California, US	28728415 2017 Mol Pharm A freeze-dried kit formulation was developed for both cyclic peptide conjugates to provide ready to use kits for the labelling with 177Lu. — 177Lu labelling of the kit formulations prepared with both cyclic MG compounds at specific activity of 58-63 GBq/µmol resulted in labelling yields >99%.

Precursor

Common precursor: —
Suppliers seen in the literature: —
Cited suppliers in indexed syntheses: CSBio
Typical final purification: —

Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-cyclo-MG1, or handle the enquiry for you.

Get in touch

Notes

Added at stage 39 (2026-09-27) from a reverse search of the PubMed corpus's own unattached articles (articles that named a real compound not yet in this reference): 2 article(s) found under this name, not yet individually researched. Target/mechanism, clinical application, indications, approval, modality, stage and production route are intentionally left empty. PMIDs: 21732165, 28728415. Stage set/updated at stage 39 from PMID 28728415: 'In the present work we have developed and preclinically evaluated a pharmaceutical kit formulation for the labeling with 177Lu of the two DOTA-conjugated cyclic MG analogues.'.